Nintedanib in Patients With Advanced Esophagogastric Cancer
This is a phase II study of Nintedanib in patients with metastatic or recurrent esophagogastric cancer. The goal of the study is to evaluate the efficacy of Nintedanib, an orally available triple kinase inhibitor targeting the receptors of the vascular endothelial growth factor (VEGF), platelet derived growth factor (PDGF), and fibroblast growth factor (FGF) receptor pathways.
Esophagogastric Adenocarcinoma
DRUG: Nintedanib
6-month Progression-free Survival (PFS), 6 months
Objective Response Rate, defined as both complete response (CR) and partial response (PR), as measured by RECIST response criteria., 3 years|Participants Evaluated for Toxicities, The severity of adverse event should be classified and recorded according to the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0., 3 years
This is a phase II study of Nintedanib in patients with metastatic or recurrent esophagogastric cancer. The goal of the study is to evaluate the efficacy of Nintedanib, an orally available triple kinase inhibitor targeting the receptors of the vascular endothelial growth factor (VEGF), platelet derived growth factor (PDGF), and fibroblast growth factor (FGF) receptor pathways.